Biokine Therapeutics Overview
Biokine Therapeutics is a clinical-stage biopharmaceutical company developing novel drugs to treat cancer. Founded in 2000 by Prof. Amnon Peled, a leading cancer and stem cell biologist at Hadassah University Hospital, Biokine has completed many years of R&D and clinical research. The company is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis. Biokine has developed a suite of unique approaches to target cancer and is conducting preclinical and clinical research on several molecules discovered and developed in-house. The companys lead drug candidate, the high-affinity CXCR4 antagonist BKT140/BL8040, is currently in a phase 2a clinical trial for the treatment of refractory and relapsed acute myeloid leukemia (AML), as well as a phase 1 clinical trial for the mobilization of stem cells. The CXCR4 receptor plays a pivotal role in the regulation of certain cancers and inflammatory diseases and is critically involved in stem cell biology and tissue regeneration. BKT140/BL8040 was licensed to BioLineRx Ltd.
Cumulative Funding Raised Over Time ($)
$750KJan 2007
Latest News
growth-positive
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications BioLineRx
BioLineRx Ltd., a clinical-stage biopharmaceutical company, has announced an agreement with Biokine Therapeutics to increase its stake in its lead oncology platform, BL-8040, from 60% to 80%. The transaction involves an upfront payment of $10 million in cash and $5 million in restricted BioLineRx shares, with Biokine also eligible to receive up to $5 million in future milestone payments. The $10 million upfront payment is being financed in full via the receipt of $10 million in debt financing from Kreos Capital. The transaction is expected to close within the next 10 days.
InvestmentAcquisition
growth-positive
BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
BioLineRx has announced a clinical research collaboration with Genentech to investigate the combination of BL-8040 with Atezolizumab in multiple oncology indications. The Phase 1b studies will evaluate the clinical response, safety, and tolerability of the combination in hematologic malignancies and solid tumors.
Partners
growth-positive
BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
BioLineRx has announced a clinical research collaboration with Genentech to investigate the combination of BL-8040 with Atezolizumab in multiple oncology indications. The Phase 1b studies will evaluate the clinical response, safety, and tolerability of the combination in hematologic malignancies and solid tumors.
Partners
growth-positive
BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML
BioLineRx has reported positive top-line results from its Phase 2 clinical trial for relapsed or refractory acute myeloid leukemia (AML). The company also identified a potential biomarker for future selection of BL-8040-responsive AML patients.
Customers
growth-positive
Cancer treatment co BioKine gets $1.2m grant
Biokine Therapeutics, Ltd. has received a $1.2 million research grant from the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor. The funding will support a Phase I/IIa clinical study to test the safety and efficacy of the companys flagship product, cancer drug BKT140. The study has been initiated at the Sheba Medical Center. Biokine Therapeutics develops pharmaceuticals that control the activity of receptors for molecules called chemokines, which play a key role in the development of cancer and inflammatory diseases.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1.95M |
| Last funding | $1.2M |
| Stage | Mature |
| Rounds | 2 |
| Investors | 2 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | biokine.com |
Locations
Rehovot, Israel
Photos & Videos
1 item(s)
Biokine Therapeutics Business
Business models
B2C
Product stage
Released
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatientsProvidersCore Technology
BiologicalsCellsTags (9)
stem-cellsbiopharmaceuticalbioprocesscancerdrug-discoverydoctorsautoimmune-diseasespatientshealthcare-providersGeographic Markets
United StatesBiokine Therapeutics Financials
$1.95M
Total funding
Undisclosed
Capital raised
$1.2M
Last funding
Mature
Funding stage
2
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$750KJan 2007
Private Equity Funding
Undisclosed Round
Jan 2007
$750K
Clal Biotechnology Industries (CBI), Amnon Peled
Non-Equity Funding
GrantEvent
Mar 2009
$1.2M
Office of the Chief Scientist
Biokine Therapeutics Lifecycle
Cumulative Funding Raised Over Time
$750KJan 2007
All Events
Undisclosed Round
Jan 2007
$750K
Clal Biotechnology Industries (CBI), Amnon Peled
GrantEvent
Mar 2009
$1.2M
Office of the Chief Scientist
Biokine Therapeutics News
6 articles
growth-positive
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications BioLineRx
BioLineRx Ltd., a clinical-stage biopharmaceutical company, has announced an agreement with Biokine Therapeutics to increase its stake in its lead oncology platform, BL-8040, from 60% to 80%. The transaction involves an upfront payment of $10 million in cash and $5 million in restricted BioLineRx shares, with Biokine also eligible to receive up to $5 million in future milestone payments. The $10 million upfront payment is being financed in full via the receipt of $10 million in debt financing from Kreos Capital. The transaction is expected to close within the next 10 days.
InvestmentAcquisition
growth-positive
BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
BioLineRx has announced a clinical research collaboration with Genentech to investigate the combination of BL-8040 with Atezolizumab in multiple oncology indications. The Phase 1b studies will evaluate the clinical response, safety, and tolerability of the combination in hematologic malignancies and solid tumors.
Partners
growth-positive
BioLineRx Announces Clinical Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab in Multiple Oncology Indications
BioLineRx has announced a clinical research collaboration with Genentech to investigate the combination of BL-8040 with Atezolizumab in multiple oncology indications. The Phase 1b studies will evaluate the clinical response, safety, and tolerability of the combination in hematologic malignancies and solid tumors.
Partners
growth-positive
BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML
BioLineRx has reported positive top-line results from its Phase 2 clinical trial for relapsed or refractory acute myeloid leukemia (AML). The company also identified a potential biomarker for future selection of BL-8040-responsive AML patients.
Customers
growth-positive
Cancer treatment co BioKine gets $1.2m grant
Biokine Therapeutics, Ltd. has received a $1.2 million research grant from the Office of the Chief Scientist of the Ministry of Industry, Trade and Labor. The funding will support a Phase I/IIa clinical study to test the safety and efficacy of the companys flagship product, cancer drug BKT140. The study has been initiated at the Sheba Medical Center. Biokine Therapeutics develops pharmaceuticals that control the activity of receptors for molecules called chemokines, which play a key role in the development of cancer and inflammatory diseases.
Investment
growth-positive
Cancer treatment co Biokine raises NIS 2.5m
Biokine, a developer of cancer treatment, has raised NIS 2.5 million in investment. The company is currently in the process of para-clinical trials for its cancer drug. Biokine was founded in 2000 by Dr. Amnon Peled and Dr. Lior Carmon. It has received research grants and funding from the EU sixth framework program. The companys cancer drug targets a receptor over-expressed in various types of cancer cells, causing them to die.
Investment
Biokine Therapeutics Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 4 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Biokine Therapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Natalia Golczar |
| Registrar ID | 512976317 |
| Crunchbase | biokine-therapeutics |
| Phone | +97289301015 |
| Last updater | Orli Wollner |
| Updater email | orlushka@gmail.com |
| Last update | 2020-08-17T00:00:00.000Z |
| Created | 2015-01-12T00:00:00.000Z |